Company Overview of Nivalis Therapeutics, Inc.
As of July 24, 2017, Nivalis Therapeutics, Inc. was acquired by Alpine Immune Sciences Inc., in a reverse merger transaction. Nivalis Therapeutics, Inc., a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis in the United States. Its lead product candidate is N91115, a small molecule inhibitor, which is in Phase II clinical trial that addresses a defect in cystic fibrosis transmembrane conductance regulator resulting from mutations. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquarter...
3122 Sterling Circle
Boulder, CO 80301
Founded in 2007
Key Executives for Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. does not have any Key Executives recorded.
Nivalis Therapeutics, Inc. Key Developments
Nivalis Therapeutics, Inc. Announces Management Changes
Jul 25 17
On July 24, 2017, Nivalis Therapeutics, Inc. completed its business combination with what was then known as Alpine Immune Sciences, Inc. (Alpine) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among the Company, Nautilus Merger Sub, Inc. (Merger Sub), and Alpine (the Merger Agreement), pursuant to which Merger Sub merged with and into Alpine, with Alpine surviving as a wholly owned subsidiary of the company (the Merger). Pursuant to the Merger Agreement, all of the directors of the Company prior to the Merger, other than two designees mutually agreed upon by the Company and Alpine to either be appointed to or remain on the board of directors, resigned as directors immediately prior to the effective time of the Merger. In accordance with the Merger Agreement, on July 24, 2017, immediately prior to the effective time of the Merger, John Moore, Howard Furst, M.D., Evan Loh, M.D., and Cynthia Smith resigned from the company's board of directors and any respective committees of the board of directors to which they belonged, which resignations were not the result of any disagreements with the company relating to the company's operations, policies or practices. Also on July 24, 2017, immediately prior to the effective time, R. Michael Carruthers, the company's Interim President and Chief Financial Officer and Janice Troha, the Company's Chief Operating Officer, resigned as officers of the company. On July 24, 2017, effective as of the effective time of the Merger, the company's board of directors appointed Mitchell H. Gold, M.D., as the Executive Chairman of the company's board of directors and the company's Chief Executive Officer and Assistant Secretary, Jay Venkatesan, M.D., as the company's President, Stanford Peng, M.D., Ph.D., as the company's Executive Vice President of Research and Development and Chief Medical Officer and Paul Rickey as the company's Senior Vice President, Chief Financial Officer and Secretary, each to serve at the discretion of the company's board of directors.
Nivalis Therapeutics, Inc. Announces Executive Changes
Jul 20 17
In connection with the expected closing of the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among Nivalis Therapeutics, Inc. (the “Company”), Nautilus Merger Sub, Inc. and Alpine Immune Sciences, Inc. (the “Merger Agreement”), R. Michael Carruthers, Interim President and Chief Financial Officer of the Company, and Janice Troha, Chief Operating Officer of the Company, each entered into a Separation and Release Agreement, dated July 11, 2017 (collectively, the “Separation Agreements”), with the Company pursuant to which the Company agreed to pay Mr. Carruthers and Ms. Troha the severance benefits, set in that certain Employment Agreement, dated January 21, 2015, by and between Mr. Carruthers and the Company, and that certain Employment Agreement, dated November 1, 2012, by and between Ms. Troha and the Company, in a single lump sum payment (rather than in 12 equal monthly installments as currently provided in their employments agreements with the Company) as well as a portion of the retention bonus previously approved by the Board of Directors of the Company for Mr. Carruthers and Ms. Troha, all in consideration for a general release of claims by Mr. Carruthers and Ms. Troha contained in the Separation Agreements that became effective July 19, 2017.
Nivalis Therapeutics, Inc. Approves Amendments to Certificate of Incorporation
Jul 20 17
Nivalis Therapeutics, Inc. at its special meeting of stockholders held on July 19, 2017 approved an amendment to the amended and restated certificate of incorporation of Nivalis to effect a reverse stock split of Nivalis’ common stock, at a ratio of one new share for every four shares outstanding, and to change the corporate name of Nivalis from “Nivalis Therapeutics, Inc.” to Alpine Immune Sciences, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 18, 2017